Hypertension is one of the most prevalent chronic cardiovascular disorders worldwide and remains a leading cause of morbidity and mortality.1 According to the World Health Organization (WHO), approximately 1.3 billion adults are affected by hypertension, with many individuals remaining undiagnosed or inadequately treated.2 Persistent elevation of arterial blood pressure significantly increases the risk of myocardial infarction, stroke, heart failure, chronic kidney disease, and premature death.3 From a physiological standpoint, blood pressure is maintained through the coordinated regulation of cardiac output, peripheral vascular resistance, blood volume, and neurohormonal mechanisms involving the autonomic nervous system, the renin–angiotensin–aldosterone system (RAAS), endothelial function, and renal sodium homeostasis.4 Any disruption in these tightly controlled physiological processes may lead to sustained hypertension.

In recent years, oxidative stress has emerged as a fundamental contributor to the pathophysiology of hypertension.5 Oxidative stress refers to an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defense systems.6 Under normal physiological conditions, ROS such as superoxide anions, hydrogen peroxide, and hydroxyl radicals serve important roles in intracellular signaling, immune defense, and vascular homeostasis.7 However, excessive ROS production overwhelms endogenous antioxidant enzymes including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) leading to cellular dysfunction and tissue damage.8

One of the principal physiological consequences of oxidative stress is endothelial dysfunction. The vascular endothelium plays a central role in regulating vascular tone through the synthesis and release of vasoactive substances, particularly nitric oxide (NO).9 Nitric oxide is a potent vasodilator that promotes smooth muscle relaxation, inhibits platelet aggregation, and suppresses vascular inflammation.10 Excessive ROS readily react with NO to form peroxynitrite, thereby reducing NO bioavailability and impairing endothelial-dependent vasodilation.11 The resulting increase in vascular resistance contributes directly to elevated blood pressure.

Oxidative stress also interacts closely with several physiological regulatory systems involved in blood pressure control.12Activation of the RAAS stimulates the production of angiotensin II, which enhances ROS generation through activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.13 Increased ROS further amplify sympathetic nervous system activity, promote vascular smooth muscle cell proliferation, and induce inflammatory cytokine release, creating a vicious cycle that perpetuates hypertension.14 Additionally, oxidative stress impairs renal function by reducing renal blood flow and altering sodium handling, thereby contributing to volume expansion and persistent increases in arterial pressure.15

Mitochondria represent another important source of ROS in hypertensive individuals.16 Mitochondrial dysfunction disrupts cellular energy metabolism and increases oxidative damage to proteins, lipids, and DNA.17 These alterations accelerate vascular aging, arterial stiffness, and structural remodeling of blood vessels, all of which are recognized physiological characteristics of chronic hypertension. Furthermore, chronic oxidative stress activates transcription factors such as nuclear factor-kappa B (NF-κB), leading to sustained vascular inflammation and fibrosis that further compromise cardiovascular function.18

Growing evidence suggests that enhancing antioxidant defenses through dietary modifications, regular physical activity, and pharmacological interventions may improve endothelial function and reduce cardiovascular risk. Although antioxidant supplementation has shown mixed clinical results, understanding the physiological mechanisms linking oxidative stress to hypertension remains essential for developing targeted therapeutic strategies. Biomarkers of oxidative stress and antioxidant status are also gaining attention as potential indicators of disease progression and treatment response.

This article provides a comprehensive physiological overview of the relationship between oxidative stress and hypertension, highlighting the underlying molecular and cellular mechanisms, alterations in vascular physiology, and potential therapeutic approaches aimed at restoring redox balance. Understanding these physiological interactions is essential for improving preventive strategies and advancing the management of hypertension in both clinical and research settings.

Study Design: A hospital-based comparative cross-sectional study was conducted to evaluate oxidative stress and antioxidant status in patients with hypertension and healthy normotensive controls. The study was carried out over a period of 12 months in the Department of Physiology in collaboration with the Department of Cardiology and the Clinical Biochemistry Laboratory. Study Population: A total of 200 participants aged 30–70 years were enrolled, comprising 100 patients with essential hypertension (cases) and 100 age- and sex-matched healthy normotensive individuals (controls). Hypertensive patients were diagnosed according to the American College of Cardiology/American Heart Association (ACC/AHA) criteria (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥80 mmHg or current use of antihypertensive medication). Inclusion Criteria: Participants aged 30–70 years with confirmed essential hypertension who provided written informed consent were included. Healthy volunteers with normal blood pressure and no history of cardiovascular or metabolic disease served as controls. Exclusion Criteria Patients with secondary hypertension, diabetes mellitus, chronic kidney disease, liver disease, malignancy, autoimmune disorders, acute infections, pregnancy, smoking, alcohol abuse, or those taking antioxidant supplements within the previous three months were excluded to minimize confounding factors affecting oxidative stress. Data Collection: A structured questionnaire was used to collect demographic information, medical history, medication use, lifestyle characteristics, dietary habits, and family history of hypertension. Anthropometric measurements including height, weight, body mass index (BMI), and waist circumference were recorded. Blood pressure was measured three times after a 10-minute rest using a calibrated automatic sphygmomanometer, and the average of the last two readings was considered for analysis. Sample Collection: Following an overnight fast of 10–12 hours, 5 mL of venous blood was collected under aseptic conditions. Serum and plasma were separated by centrifugation at 3000 rpm for 10 minutes and stored at −80°C until biochemical analysis. Laboratory Analysis: Oxidative stress was assessed by measuring malondialdehyde (MDA) using the thiobarbituric acid reactive substances (TBARS) assay. Antioxidant defense was evaluated by estimating superoxide dismutase (SOD) activity, catalase (CAT) activity, and reduced glutathione (GSH) concentrations using standardized spectrophotometric methods. Total antioxidant capacity (TAC) was determined by a commercial colorimetric assay. Routine biochemical investigations including fasting blood glucose, lipid profile, serum creatinine, and high-sensitivity C-reactive protein (hs-CRP) were analyzed using an automated clinical chemistry analyzer. Outcome Measures: The primary outcome was the comparison of oxidative stress and antioxidant biomarkers between hypertensive patients and healthy controls. Secondary outcomes included the association of oxidative stress markers with systolic and diastolic blood pressure, BMI, lipid profile, and inflammatory markers. Statistical Analysis: Data were analyzed using IBM SPSS Statistics version 26.0. Continuous variables were expressed as mean ± standard deviation (SD), while categorical variables were presented as frequencies and percentages. Independent sample t-tests were used to compare continuous variables between groups, and the Chi-square test was used for categorical variables. Pearson's correlation coefficient was applied to assess relationships between oxidative stress biomarkers and clinical parameters. Multiple linear regression analysis was performed to identify independent predictors of oxidative stress. A p-value <0.05 was considered statistically significant.

Study Population

A total of 200 participants were enrolled in the study, including 100 patients with essential hypertension (cases) and 100 healthy normotensive individuals (controls). There was no statistically significant difference between the two groups regarding age or sex distribution (p > 0.05), indicating appropriate matching. However, body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were significantly higher in the hypertensive group.

Table 1. Baseline Demographic and Clinical Characteristics of the Study Population

Interpretation: Hypertensive patients had significantly higher BMI, SBP, and DBP compared with healthy controls.

Figure 1 shows the gender distribution of participants in the hypertensive and control groups

Table 2. Comparison of Oxidative Stress and Antioxidant Biomarkers

Interpretation: Patients with hypertension demonstrated significantly elevated oxidative stress (higher MDA) and significantly reduced antioxidant enzyme activities (SOD, CAT, GSH, and TAC) compared with controls.

Table 3. Routine Biochemical Parameters

Interpretation: Hypertensive patients exhibited significantly less favorable lipid profiles and higher inflammatory marker (hs-CRP) levels than controls.

Table 4. Correlation of Oxidative Stress Biomarkers with Blood Pressure

Interpretation: MDA showed a strong positive correlation with both systolic and diastolic blood pressure, whereas antioxidant biomarkers demonstrated significant negative correlations, suggesting that increasing oxidative stress is associated with worsening hypertension.

The present study investigated the relationship between oxidative stress and antioxidant defense mechanisms in patients with essential hypertension. The findings demonstrated that hypertensive patients exhibited significantly higher levels of oxidative stress, reflected by increased malondialdehyde (MDA) concentrations, together with significantly reduced activities of antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH), and total antioxidant capacity (TAC), compared with healthy normotensive controls. These findings support the hypothesis that oxidative stress is an important physiological mechanism contributing to the development and progression of hypertension. The significantly elevated MDA levels observed in hypertensive patients indicate increased lipid peroxidation resulting from excessive production of reactive oxygen species (ROS). Under normal physiological conditions, ROS participate in cellular signaling and vascular regulation; however, excessive ROS production causes oxidative damage to lipids, proteins, and DNA. Increased oxidative stress promotes endothelial dysfunction by reducing the bioavailability of nitric oxide (NO), an essential vasodilator responsible for maintaining vascular homeostasis. Decreased NO availability leads to impaired vasodilation, increased peripheral vascular resistance, and persistent elevation of blood pressure. Our study also demonstrated significantly reduced antioxidant enzyme activities in hypertensive patients. SOD, CAT, and GSH represent the primary endogenous antioxidant defense system that protects vascular tissues from oxidative injury. Reduced activity of these enzymes suggests depletion of antioxidant reserves in response to chronic oxidative stress. The decrease in TAC further confirms an impaired antioxidant defense capacity in hypertension. These observations are consistent with previous physiological and clinical studies reporting diminished antioxidant status among patients with essential hypertension. Another important finding was the significant positive correlation between MDA levels and both systolic and diastolic blood pressure, while antioxidant biomarkers showed significant negative correlations with blood pressure values. These relationships suggest that increasing oxidative stress parallels the severity of hypertension. Oxidative stress may activate the renin–angiotensin–aldosterone system (RAAS), stimulate sympathetic nervous system activity, and enhance vascular smooth muscle cell proliferation, thereby contributing to sustained hypertension and vascular remodeling. The hypertensive group also exhibited significantly higher BMI, dyslipidemia, elevated fasting blood glucose, and increased hs-CRP levels compared with controls. These metabolic abnormalities are recognized contributors to oxidative stress and endothelial dysfunction. Elevated LDL cholesterol and triglycerides increase lipid oxidation, while chronic low-grade inflammation, indicated by higher hs-CRP concentrations, further enhances ROS production. These factors collectively accelerate vascular injury and increase cardiovascular risk in hypertensive individuals. From a physiological perspective, the findings highlight the close interaction between oxidative stress, endothelial dysfunction, inflammation, and neurohormonal regulation in maintaining blood pressure. Persistent oxidative stress disrupts vascular homeostasis, impairs endothelial nitric oxide synthesis, promotes arterial stiffness, and contributes to target-organ damage involving the heart, kidneys, and brain. Therefore, interventions aimed at reducing oxidative stress through lifestyle modification, dietary antioxidant intake, regular physical activity, and optimal antihypertensive therapy may help preserve vascular function and reduce cardiovascular complications. The present study has several strengths, including an adequate sample size of 200 participants, inclusion of age- and sex-matched controls, and comprehensive assessment of multiple oxidative stress and antioxidant biomarkers. However, certain limitations should be acknowledged. The cross-sectional design limits the ability to establish causal relationships between oxidative stress and hypertension. The study was conducted at a single center, which may limit the generalizability of the findings. In addition, dietary antioxidant intake and genetic factors influencing oxidative stress were not evaluated.

Oxidative stress is significantly associated with the development and progression of essential hypertension. Hypertensive patients exhibited increased oxidative stress and reduced antioxidant defense compared with healthy controls. These findings suggest that oxidative stress contributes to endothelial dysfunction and elevated blood pressure. Targeting oxidative stress through appropriate lifestyle modifications and effective antihypertensive therapy may help improve vascular function and reduce cardiovascular complications.

1. World Health Organization. Global report on hypertension: the race against a silent killer. World Health Organization; 2023 Sep 19.
2. Goorani S, Zangene S, Imig JD. Hypertension: a continuing public healthcare issue. International journal of molecular sciences. 2024 Dec 26;26(1):123.
3. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020 Feb;75(2):285-92.
4. Valensi P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovascular Diabetology. 2021 Aug 19;20(1):170.
5. Griendling KK, Camargo LL, Rios FJ, Alves-Lopes R, Montezano AC, Touyz RM. Oxidative stress and hypertension. Circulation research. 2021 Apr 2;128(7):993-1020.
6. Afzal S, Abdul Manap AS, Attiq A, Albokhadaim I, Kandeel M, Alhojaily SM. From imbalance to impairment: the central role of reactive oxygen species in oxidative stress-induced disorders and therapeutic exploration. Frontiers in pharmacology. 2023 Oct 18;14:1269581.
7. Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nature reviews Molecular cell biology. 2020 Jul 15;21(7):363-83.
8. Sadiq IZ. Free radicals and oxidative stress: Signaling mechanisms, redox basis for human diseases, and cell cycle regulation. Current molecular medicine. 2023 Jan 1;23(1):13-35.
9. Krüger-Genge A, Blocki A, Franke RP, Jung F. Vascular endothelial cell biology: an update. International journal of molecular sciences. 2019 Sep 7;20(18):4411.
10. da Silva GM, da Silva MC, Nascimento DV, Lima Silva EM, Gouvêa FF, de França Lopes LG, Araújo AV, Ferraz Pereira KN, de Queiroz TM. Nitric oxide as a central molecule in hypertension: focus on the vasorelaxant activity of new nitric oxide donors. Biology. 2021 Oct 14;10(10):1041.
11. Janaszak-Jasiecka A, Płoska A, Wierońska JM, Dobrucki LW, Kalinowski L. Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets. Cellular & molecular biology letters. 2023 Mar 9;28(1):21.
12. Griendling KK, Camargo LL, Rios FJ, Alves-Lopes R, Montezano AC, Touyz RM. Oxidative stress and hypertension. Circulation research. 2021 Apr 2;128(7):993-1020.
13. Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R, Eguchi S. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiological reviews. 2018 Jul 1;98(3):1627-738.
14. Wang R, Wang M, Du D, Shan Z, Bi L, Chen QH. Brain-targeted reactive oxygen species in hypertension: Unveiling subcellular dynamics, immune cross-talk, and novel therapeutic pathways. Antioxidants. 2025 Mar 28;14(4):408.
15. Arendshorst WJ, Vendrov AE, Kumar N, Ganesh SK, Madamanchi NR. Oxidative stress in kidney injury and hypertension. Antioxidants. 2024 Nov 27;13(12):1454.
16. Camargo LL, Rios FJ, Montezano AC, Touyz RM. Reactive oxygen species in hypertension. Nature Reviews Cardiology. 2025 Jan;22(1):20-37.
17. Schirrmacher V. Mitochondria at work: new insights into regulation and dysregulation of cellular energy supply and metabolism. Biomedicines. 2020 Nov 22;8(11):526.
18. Liu S, Liu J, Wang Y, Deng F, Deng Z. Oxidative stress: signaling pathways, biological functions, and disease. MedComm. 2025 Jul;6(7):e70268.